I-M. Svane - Department of Oncology, Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK),

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 18 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

66MO Early complete metabolic response predicts long-term efficacy after adoptive cell therapy using tumor-infiltrating lymphocytes

I-M. Svane, R. Andersen, H. Hendel, E. Ellebæk, T.H. Borch

Immuno-Oncology and Technology (2023): 100538

引用0浏览0引用

33P Impact of prior treatment on baseline immune biomarkers and nivolumab + relatlimab (NIVO+RELA)-induced changes in the tumor microenvironment (TME) in patients (pts) with melanoma from RELATIVITY-020

P.A. Ascierto, H. Tang, S. Dolfi, M.S. Nyakas,I-M. Svane,E. Muñoz Couselo, J.J. Grob, C.A. Gomez-Roca,V. Chiarion Sileni, K. Peltola, J. Larkin, I. Melero,

Immuno-Oncology and Technology (2023): 100502

引用0浏览0引用

“ One more chance to survive ”: the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy—a qualitative study and recommendations for future care

M. D. Egeler, E. Boomstra, M. W. Rohaan, N. M. J. Van den Heuvel, I. Fraterman, M. Delfos,L. V. van de Poll-Franse, T. H. Borch,I. M. Svane, J. B. A. G. Haanen, V. P. Retèl, A. H. Boekhout

Journal of cancer survivorship : research and practicepp.1-12, (2023)

引用0浏览0WOS引用

109P Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy

I.M. Noringriis, M. Donia, L. Bastholt, H. Schmidt,C.A. Haslund, E. Ellebæk,I-M. Svane

Immuno-Oncology and Technology (2023): 100581

引用0浏览0引用

57P Anatomical location of metastasis and composition of the final infusion product in metastatic melanoma (MM) patients treated with tumor-infiltrating lymphocytes (TIL)

J. Stoltenborg Granhøj, T.H. Borch, M. Rohaan, K. Madsen, I. Jedema, C. Nijenhuis,M. van Zon,B. Nuijen,W. Van Houdt, L. Rosenkrantz Hölmich, Ö. Met, M. Donia,

Immuno-Oncology and Technology (2023): 100530

引用0浏览0引用

48O Safety and efficacy of combined treatment with tumor infiltrating lymphocytes (TILs) and oncolytic adenovirus TILT-123 for patients with metastatic melanoma: Results from a phase I trial

T.J. Monberg, S. Pakola, B. Dreno, V. Cervera-Carrascon, E. Ellebæk, M. Donia, A. Khammari, C. Kistler, J. Manuel Dos Santos, J. Clubb, L. Haybout, B. Albieri,

Immuno-Oncology and Technology (2023): 100521

引用0浏览0引用

45P Protein biomarkers associated with organ-specific immune-related toxicity and response to management identified by proteome analysis of extracellular vesicles from plasma